Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 20;9(1):327.
doi: 10.1038/s41392-024-02058-x.

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates

Leonie Mayer  1   2   3 , Leonie M Weskamm  4   5   6 , Marylyn M Addo  7   8   9
Affiliations

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates

Leonie Mayer et al. Signal Transduct Target Ther. .

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Study overview. As recently published in Cell, Mucker et al. conducted an mpox vaccine study in non-human primates (NHP), comparing a novel mRNA vaccine (mRNA-1769) to a live-attenuated Modified Vaccinia virus Ankara (MVA) vaccine. Following vaccination, NHPs were challenged with the mpox virus. While vaccination with mRNA-1769 and MVA resulted in similar protection against lethality, mRNA-1769 vaccination led to a stronger reduction of mpox lesions and viremia and induced superior antibody titers and functionality. A multivariate correlates analysis revealed that neutralizing and Fc-mediated antibody functions were associated with vaccine-induced protection. Created in BioRender
See this image and copyright information in PMC

References

    1. Mucker, E. M. et al. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell187, 5540–5553.e10 (2024). - DOI - PubMed
    1. Berry, M. T. et al. Predicting vaccine effectiveness for mpox. Nat. Commun.15, 3856 (2024). - DOI - PMC - PubMed
    1. Freyn, A. W. et al. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci. Transl. Med.15, eadg3540 (2023). - DOI - PubMed
    1. Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol.18, 46–61 (2018). - DOI - PMC - PubMed
    1. Zuiani, A. et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell187, 1363–1373.e12 (2024). - DOI - PubMed

LinkOut - more resources